These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 35002037)
1. Niraparib for ovarian cancer. Aust Prescr; 2021 Dec; 44(6):208-209. PubMed ID: 35002037 [No Abstract] [Full Text] [Related]
2. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. Meng J; Peng J; Feng J; Maurer J; Li X; Li Y; Yao S; Chu R; Pan X; Li J; Zhang T; Liu L; Zhang Q; Yuan Z; Bu H; Song K; Kong B J Transl Med; 2021 Oct; 19(1):415. PubMed ID: 34620163 [TBL] [Abstract][Full Text] [Related]
3. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559 [TBL] [Abstract][Full Text] [Related]
4. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU; Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695 [TBL] [Abstract][Full Text] [Related]
6. Niraparib for the treatment of ovarian cancer. Essel KG; Moore KN Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447 [TBL] [Abstract][Full Text] [Related]
7. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000 [TBL] [Abstract][Full Text] [Related]
8. Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. Takehara K; Matsumoto T; Hamanishi J; Hasegawa K; Matsuura M; Miura K; Nagao S; Nakai H; Tanaka N; Tokunaga H; Ushijima K; Watari H; Yokoyama Y; Kase Y; Sumino S; Suri A; Itamochi H; Takeshima N J Gynecol Oncol; 2021 Mar; 32(2):e21. PubMed ID: 33470063 [TBL] [Abstract][Full Text] [Related]
9. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391 [TBL] [Abstract][Full Text] [Related]
10. Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series. Gabrail N; Smith C Am J Case Rep; 2020 Nov; 21():e927008. PubMed ID: 33191394 [TBL] [Abstract][Full Text] [Related]
11. Niraparib in ovarian cancer: results to date and clinical potential. Caruso D; Papa A; Tomao S; Vici P; Panici PB; Tomao F Ther Adv Med Oncol; 2017 Sep; 9(9):579-588. PubMed ID: 29081841 [TBL] [Abstract][Full Text] [Related]
12. Niraparib for the treatment of ovarian cancer. Kanjanapan Y; Lheureux S; Oza AM Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768 [TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751 [TBL] [Abstract][Full Text] [Related]
17. Niraparib: A Review in Ovarian Cancer. Heo YA; Duggan ST Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633 [TBL] [Abstract][Full Text] [Related]
18. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175 [TBL] [Abstract][Full Text] [Related]
19. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Moore K; Chan JK; Secord AA; Patel MR; Callahan T; Guo W; Zhang ZY Cancer Chemother Pharmacol; 2019 Apr; 83(4):717-726. PubMed ID: 30680521 [TBL] [Abstract][Full Text] [Related]
20. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Wu L; Zhong L J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]